Study identifies new therapeutic candidate for KRAS-driven pancreatic cancer

Tamara Ceaikovski

Oncotarget Jun 8 2026 A new research paper was published in Volume 17 of  Oncotarget  on June 3, 2026, titled "The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation." The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health in Tallahassee, Florida. Pancreatic ductal adenocarcinoma is among the

din zilele anterioare